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1. INTRODUCTION 
1.1. RESEARCH QUESTION AND PROBLEM FORMATION 
Spain is well known for its altruism when it comes to transplants. The National 
Transplant Organisation states the number of kidney transplants in around 3000 per 
year nationwide 1 (Figure 1). This high amount of donation makes it much more 
likely for a patient in end-stage renal disease to get the treatment needed for curing 
the disease: a new kidney. 
 
Figure 1: Number of kidney transplants in Spain from 2000 to 20171 
Although there are higher chances of getting access to a donor kidney, kidney 
disease’s incidence is increasing rapidly as the life expectancy of the population 
increments. Thus, physicians are working to span the criteria for an organ to be 
considered adequate for donation: Expanded Criteria Donor (EDC).2,3,4 
For considering those organ suitable for donation, the storage and maintenance in 
between the extraction and the placement is key.  Static cold storage (CS) is 
generally used to preserve donor kidneys until its placement in the recipient. 
However, few studies in the latest 15 years have addressed the possibility of a 
perfusion machine with continuous hypothermic perfusion to maintain the organ in 
perfect preservation during the time of cold ischemia. 
This systematic review aims to go through the existent data on hypothermic machine 
perfusion (HMP) up to the date to address this possibility.  
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1.2. BASICS ON CHRONIC KIDNEY INSUFFICIENCY  
Renal transplantation is the final solution to a variety of diseases leading to chronic 
terminal kidney insufficiency. 
 
1.2.1. Chronic terminal kidney insufficiency: definition, grades, causes, 
symptoms, diagnosis and treatments.  
Chronic terminal kidney insufficiency, also called end-stage renal disease, occurs 
when chronic kidney reaches an advanced state. In this situation, the kidneys are no 
longer able to work as they should to meet the body's needs. 6,7,8 
Kidneys main function is to filter wastes and excess fluids from the blood, which are 
then excreted through urine. When kidneys lose their filtering capabilities, dangerous 
levels of fluid, electrolytes and wastes can build up in the body. 
1.2.1.1. Stages 
Kidneys decrease their capacity gradually. This characteristic allows us to classify 
the disease into five different stages of kidney insufficiency (Table 1). To determine 
the stage of kidney disease, we perform a blood test to check the glomerular filtration 
rate (GFR). The GFR provides us with an approximate measure of how much blood 
the kidneys filter each minute according to the clearance of creatinine, recorded as 
millilitres per minute (mL/min). As the GFR declines, so does the kidney function. 
When the person’s kidneys cannot at a level that's necessary for day-to-day life, we 
say that the patient is at end-stage renal disease. End-stage renal disease usually 
occurs when kidney function is less than 10 percent of normal. 
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Table 1. Stages for kidney disease. 
Kidney disease stage GFR, mL/min Kidney function 
American National Kidney Foundation 
Stage 1 90 or above 
Normal or near-normal kidney 
function + symptoms * 
Stage 2 60 to 89 
Mild loss of kidney function + 
symptoms * 
Stage 3a 45 to 59 
Mild to moderate loss of kidney 
function 
Stage 3b 30 to 44 
Moderate to severe loss of kidney 
function 
Stage 4 15 to 29 Severe loss of kidney function 
Stage 5 Less than 15 Kidney failure 
GFR: glomerular filtration rate 
*A GFR between 60 and 120 without any symptoms related to renal failure is 
not considered chronic renal disease. A GFR below 60, with or without 
associated symptoms will be considered chronic renal disease. 
 
1.2.1.2. Causes 
There are multiple conditions that can impair kidney function leading to kidney 
damage that can worsen over several months or years. The most common diseases5 
that can generate function lose are: 
• Type 1 or type 2 diabetes  
• High blood pressure 
• Glomerulonephritis  (inflammation of the kidney's filtering units or 
glomeruli) 
• Interstitial nephritis (an inflammation of the kidney's tubules and surrounding 
structures) 
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• Polycystic kidney disease 
• Prolonged obstruction of the urinary tract, from conditions such as enlarged 
prostate, kidney stones and some cancers 
• Vesicoureteral reflux 
• Recurrent pyelonephritis (kidney infection)  
 
1.2.1.3. Symptoms 
When kidneys start decreasing their function the appearance of symptoms may vary 
in each patient. Some show early symptoms with little decrease of the GFR, while 
other kidneys are highly adaptable and able to compensate for lost function and 
because of it the patient won’t show any until progressed end-stage renal disease.  
Early in chronic kidney disease, you may have no signs or symptoms. Signs and 
symptoms might include: 
• Nausea 
• Vomiting 
• Loss of appetite 
• Fatigue and weakness 
• Sleep problems 
• Changes in how much you urinate 
• Decreased mental sharpness 
• Muscle twitches and cramps 
• Swelling of feet and ankles 
• Persistent itching 
• Chest pain, if fluid builds up around the lining of the heart 
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• Shortness of breath, if fluid builds up in the lungs 
• High blood pressure (hypertension) that's difficult to control 
However, these signs and symptoms are very nonspecific, meaning they can also be 
caused by other illnesses. 
  
1.2.1.4. Diagnosis  
In consequence to the inconstancy of signs and symptoms, diagnosis of renal disease 
may result difficult. Often patients suffering from diseases known for causing kidney 
damage are tested for it. Tests and exams to detect end-stage renal disease may 
include: 
• A discussion of your health history, including personal and family health 
history. 
• A physical exam, including height, weight and blood pressure. We must also 
looks for signs of heart or blood vessels problems and a neurological exam. 
• Blood tests, to measure the amount of waste products, such as creatinine and 
urea, in the blood. 
• Urine tests, to check the level of the protein albumin in your urine, as a high 
albumin level may indicate kidney disease. 
• Imaging tests, such as ultrasound, magnetic resonance imaging or a 
computed tomography scan, to assess kidneys' structure and size and look for 
morphological abnormalities. 
• Taking a sample of kidney tissue (biopsy), to examine under a microscope 
to learn what type of kidney disease and how much damage there is. 
These tests may be repeated over time to follow the progress of kidney disease. 
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1.2.1.5. Treatment 
At early stages of chronic kidney disease, the main focus of treatment is the cause of 
that damage (controlling sugar blood levels, blood pressure…). When the damage 
increases up to end-stage renal disease, treatment may include: dialysis and/or kidney 
transplant. 
Dialysis is a procedure in which a filter different from the filters in the kidney takes 
over kidneys’ function. The dialysis filter removes extra fluids and waste products 
from blood, restoring electrolyte levels, and helping control of the blood pressure. 
There are several methods of dialysis, being the most common ones peritoneal 
dialysis and hemodialysis. 9 
• Peritoneal dialysis 
During peritoneal dialysis, the filters used are in the same patient’s abdomen. Blood 
vessels in the abdominal lining called peritoneum fill in for the kidneys with the help 
of a fluid that washes in and out of the peritoneal space. Peritoneal dialysis’ main 
benefit is that it can be done at home, so the patients won’t need to stay for long 
hours at a hospital. 
• Hemodialysis 
In the so-called hemodialysis, a machine does the work of filtering harmful wastes, 
salts and fluid from your blood. The disadvantage of hemodialysis is the long hours 
spent in medical facilities as it is rarely done at the place of residence 
However, dialysis is not a definitive solution. The only permanent solution would be 
transplantation of a healthy kidney.   
 
1.2.2. Kidney transplantation:  
Kidney transplant is the surgical procedure to place a healthy kidney from donor into 
a person whose kidneys no longer function properly. This procedure is often the 
treatment of choice for kidney failure compared to a lifetime on dialysis. The 
indication for kidney transplantation is to have a chronic terminal kidney 
insufficiency stage V or end-stage renal disease.   
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Kidney transplantation have benefits in comparison to dialysis, as the procedure 
imply a better quality of life, lower death risk, fewer dietary restriction and overall 
lower treatment cost. 
Unfortunately, for certain people with kidney failure, a kidney transplant may be 
more risky than dialysis. There are certain conditions that may prevent the patients 
from being eligible for a kidney transplant, such as advanced age, severe heart 
disease, active or recently treated cancer, dementia, alcohol or drug abuse or any 
other factor that could affect their ability to safely undergo the procedure and take 
the medications needed to prevent organ rejection. 
Also, for treating end-stage kidney disease, one donated kidney is needed to replace 
two failed kidneys. This fact makes living-donor kidney transplantation an option, as 
one kidney would be enough for the donor to survive and could replace the function 
of the two failed kidneys in the recipient. 
If a compatible living donor isn't available, the patient may be placed on a kidney 
transplant waiting list to receive a kidney from a deceased donor. 
 
1.2.2.1. Types 
Therefore, we could classify the types of kidney transplantation into two main 
groups: living donor kidney and deceased-donor transplant. 
• Living-donor kidney transplant 
As mentioned, only one healthy kidney is needed to replace two non-functioning 
kidneys, making living-donor kidney a possibility. 10 The donor would also live with 
one healthy kidney, enough to cover all functions. In comparison with deceased-
donor kidney transplant, there are several benefits: 
• Less or no time on a waiting list, as donors are usually people known 
by the patient 
• Better short- and long-term survival rates 
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• The possibility to schedule the transplant. Decease-donor 
transplantations are usually conducted as an emergency procedure. 
• Living-donor kidneys have a lower rate of delayed graft function 
(DGF). 
Other risks of every transplant (associated with the surgery, organ rejection and side 
effects of anti-rejection medications) are similar in both types. 
 
• Deceased-donor kidney transplant:  
Deceased-donor kidney transplant is when a kidney from a recently deceased person 
is removed and placed in a recipient who is in need of transplantation. 
Inside this classification we can split the donors into donors after brain death (DBD) 
and donors after circulatory death (DCD), which could also be named asystolic 
donors or non-heart-beating donors (NHBD).  
Deeper in this last subcategory, we find the Maastricht classification (Table 2) of 
donors after circulatory death, first stated in the nineties, which was agreed as the 
growing experience in DCD led up to the need to distinguish several categories of 
potential donor in different end-of-life situations. 
It’s useful as it is able to characterize the different DCD situations and the different 
categories of donors, considering technical and medical aspects (such as organ 
viability, preservation modalities or graft survival) and ethical aspects. Attempts to 
improve the Maastricht classification have focused on adding more categories, with 
the objective of distinguishing the different ischaemic insults to the organ and 
consequently different outcomes, but many attempts have not settled in, as one of the 
reasons Maastricht is used is its simplicity and usefulness. Only the modified 
Maastricht classification of DCD done in Paris in 2013 (Table 3) has seemed to 
solidify as it kept intact the simplicity of the original classification.  
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Table 2. Maastricht classification of donors after circulatory death. 
Category Description Control 
I Dead on arrival Uncontrolled 
II Unsuccessful resucitation Uncontrolled 
III Awaiting cardiac arrest Controlled 
IV Cardiac arrest while brain dead Uncontrolled 
 
Table 3. The Modified Maastricht Classification of DCD 
Category Situation Description 
I 
Found dead 
Sudden unexpected CA without 
any attempt of resuscitation by a 
life-medical team; WIT to be 
considered according to National 
life-recommendations in place; 
reference to in- or out-of-hospital 
life-setting 
IA Out of hospital 
IB In hospital 
II 
Witnessed cardiac arrest 
Sudden unexpected irreversible CA 
with unsuccessful resuscitation 
life-by a life-medical team; 
reference to in or out of hospital 
life-setting 
IIA Out of hospital 
IIB In hospital 
III 
Withdrawal of life-sustaining 
therapy 
Planned withdrawal of 
life-sustaining therapy* 
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IV Cardiac arrest while life-brain dead 
Sudden CA after brain death 
diagnosis during donor 
life-management but prior to planes 
organ recovery. 
 
CA= circulatory arrest. 
* This category mainly refers to the decision to withdraw life-sustaining 
therapies. Legislation in some countries allows euthanasia (medically assisted 
CA, expected CA) and organ donation described as the fifth category. 
  Category I 
Dead on arrival includes victims who arrive to the hospitals after accidents that have 
not been resuscitated (for clear reasons of death). These deceased patients could 
arrive to the emergency department and become a donor if the organs are deemed 
appropriate for donation. The main criterion for acceptance for donation is warm 
ischemia time (WIT), which is the time between the circulatory arrest and the start of 
the cooling. This time should be of less than 45 min to consider the organs adequate 
for donation. Due to the commonly uncertain duration of WIT, there are few 
examples of successful organ donation in this category. 
  Category II 
Unsuccessful resuscitation is a category that includes patients brought to the 
emergency room while being resuscitated. If the cardiopulmonary resuscitation 
(CPR) is unsuccessful, the patient would be declared dead. According to the 
Maastricht classification, a period of “no-touch” after cardio-circulatory arrest (CA) 
to ensure a situation equivalent to brain death. If the deceased patient is a donor, the 
hospital crew can immediately proceed to the cooling preservation,  
 
Timing in the uncontrolled DCD process. 
1. No flow: Kidney ≤30 min; Liver ≤ 15 min 
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2. CPR duration: ≥30 min 
3. No-touch period: 2 min to 20 min 
4. Total WIT: 120 min to 150 min 
In some countries, which include Spain, two subcategories were added in the Paris 
2013 reformulation due to different logistic conditions according to the site where 
CA occurs: IIa for out-of-hospital and IIb for in-hospital. However, most of this 
cases occur out of the hospital, so this further classification is not always used. 
  Category III 
Awaiting cardiac or circulatory death includes patients whose circulatory death 
occurs after withdrawal of life-sustaining therapies (WLST), previously planned and 
agreed with patient and/or families. That’s why we consider it a controlled situation, 
as the fact that the CA is planned allows the medical practitioners to shorter as much 
as possible the ischemia time, which is very beneficial for all organs to be donated.  
Timing of the controlled DCD process. 
1. Functional WIT starts when SBP is ≤ 50 mmHg or ≤ 60 mmHg 
2. No-touch period: 2 min to 20 min 
  Category IV 
Cardiac arrest in a brain-dead donor is a category that includes patients diagnosed 
with brain death who suffer an unexpected arrest before the planned organ recovery. 
Firstly, medical practitioners should try to maintain the organ circulation and 
perfusion but in case of failure, the patient would be included in the category IIb 
(uncontrolled CA inside the hospital).  
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1.3. THEORETICAL FRAMEWORK ON THE HYPOTHERMIC 
PERFUSION MACHINE  
1.3.1. Kidney preservation and storage  
The donated kidney can be transported stored on ice or connected to a machine that 
provides oxygen and nutrients until the kidney is transplanted into the recipient. The 
problem with cold storage (CS) is that long periods of cold ischemia are strongly 
associated with delayed graft function (DGF). As DGF is linked to lower graft 
survival, perfusion machines were designed to deliver nutrients, substrates and 
remove toxic waste products during that time.  
This machine pumps continuously cold preservation solutions through the renal 
artery to the kidneys. In Europe, there are two different devices commercialised:  
Two different devices are currently commercially available in Europe: LifePort 
Kidney Transporter and RM3. However, LifePort is the only machine that allows 
transportation commercialised in Europe up to date.  
 
1.3.1.1. LifePort Kidney Transporter 12 
The machine keeps the kidney in a bath of preservation solution surrounded by an ice 
box. Every use of the machine requires different perfusion kits, which are specific 
consumables and preservation solutions to each device (see Figure 2). 
 
Figure 2: LifePort Kidney Transporter perfusion kit  
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The solution is withdrawn from the reservoir and pumped through the renal artery. It 
can also monitor several values which could potentially be of use to assess graft 
quality11: resistive index, temperature, pressure and flow dynamics.(see Figure 3). 
 
Figure 3: LifePort Kidney Transporter  
 
The procedure is simple. After the extraction of the kidney, the following steps must 
be taken for cannulisation of the kidney: 
1. Place both the kidney and the proper cannula into the sterile field. Multiple 
cannulas are available, depending on the characteristics. 
2. Open the cannula. 
 
Figure 4.1: Opening the cannula.  
 
3. Insert the aortic patch through the cannula ring. 
4. Ensure the patch covers the entire sealing ring. 
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Figure 4.2: Insertation of aortic patch through cannula ring 
 
5. Close the cannula, securing the tissue between the two halves. 
6. Secure the cannula by wrapping the two straps and fix them to their posts. 
 
Figure 4.3: Closing and sealing of aortic patch 
 
7. Make a small flow of solution through the cannula to ensure there are no 
leaks. Correct if there are.  
8. Place the kidney in the machine and snap the cannula into the correct 
position. 
 
Figure 4.4: Placing of kidney in machine 
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9. Adjust the height and rotation of the cannula to the correct position the vessel. 
10. Ensure there are no twists or occlusions in the vessel.   
11. Secure the organ by adjusting the net. 
 
Figure 4.5: Securing kidney in machine 
 
After cannulisation, the kidney should be secured in the machine and connected to 
the solution flow as shown in the Figure 5. 
  
Figure 5: Kidney properly placed in LifePort Transporter 
 
Once properly placed, the machine will provide the parameters of study: pressure, 
flow, resistance and temperature. Continuous perfusion is thought to decrease the 
vascular resistance and increment the flow into the organ, as the constant flow acts as 
a vasodilator. The operator will settle the systolic pressure, and it may be lower than 
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the established but never higher. Finally, the temperature will be lowered by placing 
ice into the ice container, maintaining at all times a temperature between 0º and 4ºC.   
 
2. OBJECTIVES.  
The objective of the present study is to analyse advantages of hypothermic machine 
perfusion and its usefulness in comparison to cold storage, focusing on the following 
items: 
The final outcome of a transplant is the general survival of the organ in the recipient. 
Thus one of the main areas of focus will be the comparison of global graft survival 
(GS) in cold storage versus hypothermic machine perfusion and the indications of the 
HMP over CS.  
Furthermore, other interesting area to work in is the time in between the placement of 
the kidney and the time it starts working properly. After the transplant, patients 
usually have to undergo dialysis for an inconstant period of time. A contrast between 
the delayed graft function (DGF) in kidneys stored in ice versus those in hypothermic 
perfusion in the latest studies will be conducted. 
There are also economic differences among cold storage and hypothermic perfusion. 
Analysis of the overall efficiency will be aimed, as it is crucial for a transplantation 
program financed publicly as Spain is.  
Finally, the monitoring of the graft’s constants is being studied in order to determine 
if that information is enough to consider an organ valid for transplantation, 
substituting current analysis such as a biopsy.  
To sum up, the main objectives of this study are: 
1. Cold ischemia versus hypothermic machine perfusion in global graft survival 
and delayed graft function. 
2. Renal resistance as an indicator of graft quality. Prognostic value of graft 
monitoring. 
3. Economic impact of the introduction of the hypothermic machine perfusion in 
the kidney transplant programs. 
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3. METHODS. 
This study is a systematic review of the scientific information about the current data 
on hypothermic machine perfusion. The main source of information was medical 
databases, where a search for systematic reviews and clinical trials was made. The 
search aimed to obtain actual, complete, wide information in order to be able to 
answer concrete objectives previously established.  
Initially, several basic researches were made on Pubmed and/or UpToDate for the 
terms “Chronic terminal kidney insufficiency”, “ Kidney transplant”, “Maastricht 
classification” and “Kidney donation”. This preliminary search also included 
LifePort Kidney Transporter Operator’s Manual for further information on the 
theoretical background of the hypothermic machine perfusion. 
Thereafter, a research was conducted for the articles to be included in the review. A 
primary examination was made under the search on Pubmed of “hypothermic 
machine perfusion”, including free full text articles publish in the last 10 years. The 
inclusion of “AND kidney” and specification of humans articles were necessary, as 
many of the results were based on animals and/or liver perfusion. From the 25 
studies, only 11 were included as the rest studied other data not associated with the 
objectives settled. 
Further research included Ovid database, which provided access to Embase and 
Medline resources. Again, full texts were searched, and older articles were included 
to analyse the progress on the machine. Under the name “delayed graft function 
AND hypothermic kidney machine perfusion”, human, full text in both English and 
Spanish was searched, leading to 29 studies, 20 of which were included on this 
review.  
To tackle the objective of the machine being able to replace other methods of 
assessing kidney graft quality, a search in Ovid database was made involving the 
search “hypothermic machine perfusion kidney quality” and also “hypothermic 
kidney machine perfusion prognosis” in humans. Out of this search, 4 articles were 
included in the review.  
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Finally, for the economic search, same procedural was followed for “hypothermic 
kidney machine perfusion economic”. 11 articles were included as many only 
involved the cost of the procedure in a determined centre.  
To sum up, the final number of 44 studies were incorporated to the review, including 
general articles, studies focused in global graft survival and delayed graft function, 
evaluations of the machine to assess kidney graft quality and economic studies. 
 
4. OUTCOMES:  
4.1. COLD ISCHEMIA VERSUS HYPOTHERMIC MACHINE PERFUSION 
IN GLOBAL GRAFT SURVIVAL AND DELAYED GRAFT FUNCTION. 
The analysis of outcomes regarding global graft survival and delayed graft function 
includes several clinical trials, observational studies and also 4 systematic reviews on 
the subject. Lower delayed graft function was thought to increase the global graft 
survival, leading to study if such assumption was based on evidence. 
Several articles included a difference between dead after cardiac arrest (DCD) and 
expanded criteria donors (ECD) versus donors after brain dead (DBD). Such 
specifications vary, and some studies obtained different outcomes depending on the 
donor type.  
Moers et al.13 followed 336 international donors for a year. Each donor had one 
kidney maintained in cold ischemia and the other in hypothermic machine perfusion. 
The study assumed that allografts from donors after cardiocirculatory death are 
known to have higher rates of delayed graft function.14, 15 The use of such grafts is 
increasing in most countries and so methods to decrease DGF should be studied. 
They observed that out of the 336 followed patients; delayed graft function was 
developed in 70 patients in the machine-perfusion group versus 89 in the cold storage 
group. As for one-year graft survival, it was superior in the machine perfusion group 
(94% vs 90%, p=0.04). Therefore, they concluded that machine perfusion could be 
considered to have a beneficial effect on the short-term outcome in all common types 
of deceased-donor kidney transplantation. 
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Patel et al. 16 decided to study the reduction in DGF rates specially focusing on 
donors after cardiac arrest, as HMP is known to be decrease DGF in all kinds of 
donors. 14, 17,18,19 Basing on that information, they assume that the DCD group would 
benefit from the HMP the most and so the study aims to review the outcomes for 
DCD kidneys in CS versus HMP. A multicentre observational study was conducted, 
in which 4529 kidneys were storage in cold and 864 were placed in the perfusion 
machine during 8 years (January 2007- December 2015). Their overall conclusion 
for delayed graft function was a considerable decrease on the machine perfusion 
group (34.2% versus 42%, p= 0.001), which concurs with the known data. However, 
in the analysis of the global graft survival there is no significant evidence of an 
association between preserving the kidneys in CS or HMP (p= 0.452), meaning that 
even if the delayed graft function is lower using the machine there are no proven 
difference in the global survival.  
Gallinat et al. 20 assume the evidence stating that delayed graft function is lower and 
global graft survival is increased given by Moers et al. 13 However, they consider 
insufficient the evidence on expanded criteria donors, so they aim to study those 
differences in their centre during 3 years. They studied 43 expanded criteria patients 
whose kidneys were one preserved in cold ischemia and the other attached to the 
hypothermic machine perfusion. Included donors were between 60 and 82 years. Out 
of the 43 pairs of ECD studied, delayed graft function was significantly lower in the 
HMP group (11.6% versus 20.9%, p=0.024). The study showed that regarding global 
graft survival there is, as shown in Figure 5, a tendency toward improved graft 
survival in HMP although it has not reached significance.  
 
 
Figure 5. Gallinat et al. Global Graft Survival in Machine Perfusion Group versus Cold Storage Group 
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Additional studies show precisely the evidence in the difference in the delayed graft 
function depending on the storage of the graft. As shown in Table 4, outcomes from 
several studies point that there is a significant decrease on the machine perfusion 
group regarding DGF. However, studies on graft survival do not reach the statistical 
signification, showing in Table 5 nothing more than a tendency towards 
improvement of the global graft survival in machine perfusion group.  
 
Table 4. Delayed Graft Function in Machine Perfusion Group versus Cold Storage Group in latest studies.  
Main author, 
year 
Sample size DGF in Machine 
Perfusion Group 
DGF in Cold 
Storage Group 
P Value 
Moers et al. 
2009 13 
336 pairs 
672 transplants 
20.8 % 26.5% 0.01 
Patel et al.,  
2018 16 
4529 in CS 
864 in MP 
34.2% 42% 0.001 
Gallinat et al., 
2016 20 
43 pairs 
86 transplants 
11.6% 20.9% 0.024 
Jochmans et al., 
2010 17 
164 53.7% 69.5% 0.025 
Treckmann et 
al., 2010 21 
82 pairs 
164 transplants 
22% 29.7% 0.047 
Matsuoka et al., 
2006 22 
139 26% 37% 0.001 
 
Table 5. Graft Survival in Machine Perfusion Group versus Cold Storage Group in latest studies.  
Main author, 
year 
Sample size Graft Survival in 
Machine 
Perfusion Group 
Graft Survival 
in Cold 
Storage Group 
P Value 
Moers et al. 
2009 13 
94 94 % 90% 0.04 
21 
Patel et al.,  
2018 16 
4529 in CS 
864 in MP 
- - 0.452 
Gallinat et al., 
2016 20 
43 97.7% 88.4% 0.089 
Jochmans et al., 
2010 17 
164 95.1% 93.9.% 0.062 
Treckmann et 
al., 2010 21 
82 pairs 
164 transplants 
92.3% 80.7% 0.164 
Matsuoka et al., 
2006 22 
139 - - 0.49 
 
4.2. RENAL RESISTANCE AS AN INDICATOR OF GRAFT QUALITY. 
PROGNOSTIC VALUE OF GRAFT MONITORING. 
The hypothermic perfusion machine enables the operator to monitor several 
indicators; more specifically LifePort kidney transportation machine shows 
temperature, flow, pressure and resistance. No evidence has been proven regarding 
temperature, flow and pressure. Resistance index has however proven to be a good 
early indicator for delayed graft function or low glomerular filtration rate.  
Jochman et al. 23 considered that even if vascular renal resistance (RR) during 
hypothermic machine perfusion is frequently used as an indicator of graft quality; 
such association has not been validated. Thus, the study collected RR values of 302 
kidneys maintained in the hypothermic machine perfusion and studied the 
association between RR and delayed graft function and 1-year graft survival. After 
the study, they concluded that a RR could be use as an additional parameter to assess 
the graft. RR values over 0.3 mmHg/mL/min were proven to be associated with 1-
year graft failure. Overall, they concluded that RR is an independent risk factor for 
the development of DGF and 1-year graft failure, not useful as a stand-alone 
assessment as more parameters are needed to achieve needed accuracy.  
Sandal et at.24 conducted a retrospective cohort study during 5 years. After studying 
274 kidney transplants, they reach a similar outcome. Kidneys with higher RR 
tended to had a lower glomerular filtration rate than those with a lower RR (102.72 ± 
22 
27.51 versus 94.49 ±30.36, p = 0.01). Taken together all their findings, the 
summarize stating that RR is an independent predictor of long graft survival. Out of 
the studies regarding RR as a prognostic factor, the one conducted by Sandal et al. 
provides the longest follow-up to date when it comes to studies using LifePort 
machines. 
Different studies evaluating transplants by parameters of the LifePort machine have 
tried to conclude on a renal resistance threshold during hypothermic machine 
perfusion. These results are shown in Table 6 with the general outcome of the study. 
 
Table 6. Evaluation of RR as a prognosis parameter in studies using LifePort machine.  
Main author, 
year 
Threshold 
(mmHg/mL/min) 
Sample size Follow up Outcome 
Sandal et al. 
2018 24 
0.4 and 0.2 274 5 years 
RR during HMP is 
associated with lower GFR 
Burgos 
Revilla et al. 
2015 29 
0.3 and 0.4 90 1 year 
RR is not predictive of 
graft survival 
Yushkov et 
al. 2012 30 
<0.2, 0.2-0.3, 
>0.3 
454 1 year 
RR>0.3 is predictive of 1-
year graft survival 
Jochmans et 
al. 2011 23 
None 336 1 year 
Terminal RR predictive of 
graft failure 
 
Gelpi et al 31, an independent study using only DCD kidney transplant stated a 
precise threshold for RR. A total of 194 transplants were included and the factor to 
study was a glomerular filtration rate lower than 30 mL/min at 6 months after 
transplantation. They concluded that for RR over 0.3 there was a 2.16 higher rate of 
GFR lower than 30mL/min in the group of recipient under 60 years, comparing to an 
almost 18 higher rate in the recipients over 60.  
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4.3. ECONOMIC IMPACT OF THE INTRODUCTION OF THE 
HYPOTHERMIC MACHINE PERFUSION IN THE KIDNEY TRANSPLANT 
PROGRAMS.  
Multiple studies have proven the benefits of hypothermic machine perfusion in 
avoiding or shortening delayed graft function and the potential of monitoring 
parameters such as pressure or renal resistance. With all the evidence in favour of the 
perfusion machine, next step to the introduction in the transplant programs is to 
assess the costs and to perform cost-efficiency studies. Although 11 studies were 
included and reviewed, only results from Gomez et al. are shown in this report, as it 
is the only study based on the Spanish public transplant program.  
Gomez et al. 42 assumes that MP could be the standard procedure for kidney 
transplantation in expanded criteria donors one day, and however, machine perfusion 
remains way more expensive than cold storage. Thus, they aim to study a cost-
effectiveness analysis, to estimate the economic impact of incorporating the LifePort 
machine into the hospital policy of extended criteria donors.  
They compared prospective costs estimation depending on the diagnosis-related 
group the recipients is included in and the possible outcomes of the transplant. 
Different outcomes included the possibility of delayed graft function and primary 
non-function, factors that would increase the cost of the transplant as the patients 
would stay for a longer period in the hospital and require dialysis.  Unit costs used to 
calculate the treatment costs are included in Table 7. 
 Table 7. Direct Medical Costs and Prices based on Diagnosis-Related Groups42 
 
24 
In the outcome analysis factors that would mean a higher final price such as hospital 
stay, dialysis needed and resource consumption were assessed and included in Table 
8.  
 
Table 8. Differences Between Expected Costs for MP and CS42 
 
 
All in all the study showed than even if the initial costs of machine perfusion are 
hhigher than cold storage, there overall analysis estimates than MP would actually 
save an average of $505 in comparison to CS. In this scenario, they conclude than 
MP technology is cost-effective in kidney transplantation program for extended 
criteria donors. 
 
5. CONCLUSION 
This systematic review sought to assess different aspects of the use of hypothermic 
machine perfusion versus the widely extended use of cold storage. Although the 
review was statistically significant in some points, much more research is needed in 
order to state most of the issues. 
Regarding hypothermic machine perfusion as a tool to reduce the frequency of 
delayed graft function as well as its duration there is clinical evidence that support 
this hypothesis. Deeper in this theory, it is now known that the grafts that would most 
benefit from the use of HMP are those extended criteria donor grafts, as these grafts 
present the highest rate of delayed graft function.  
25 
However, looking closer to the global graft survival we might deduct that if delayed 
graft function is one of the main cause of global graft survival, reducing such cause 
would immediately reduce the quota of graft failure. Although evidence does show a 
tendency towards that idea, there is not yet enough clinical experience and research 
on the topic so as to reach the statistical significance.  
Moving forward, while reviewing the published work on the different parameters to 
assess graft quality little literature was found. Nevertheless we can come to the 
conclusion that when giving graft prognosis renal resistance constitutes a very useful 
parameter to include among others, but should not be used as a stand alone criteria. 
As for the precise parameter, evidence points at a resistance not higher than 0.3 
mmHg/mL/min to predict the most optimal transplant results.  
Final point assessed, the economic impact of the implementation of machine 
perfusion in transplant programs. This area is considerably the one most research is 
needed, as literature so far include different costs for each centre, with different 
politics on the topic and thus are subject to the location of the study. 
 
Overall several difficulties were found while reviewing this area: 
• There is a lack of enough clinical evidence in our country, based primarily to 
the scarcity of personnel to gather data and the low habit to use the machine, 
as it requires longer preparation and qualification not all workers possess.  
• Although systematic reviews do exists, the literature to review is limited and 
so not many studies are included. Longest review in literature, San Miguel et 
al.43 includes 9 clinical and is primarily focused in Belgian kidney 
transplantation program. 
• Evidence found is restricted to specialised centres with high experience on the 
subject. Thus, it is difficult to overlap to smaller clinical centres with lower to 
none experience. 
• There is a lack of longer follow up of transplants after using HMP. Longest 
study (Sandal et al. 24) followed up for just 5 years after transplantation. 
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• Before the year 2000 all the studies were made based on machines different to 
LifePort, which showed no monitoring and/or were not able to be transported.  
As a final result, the conclusions are consistent with most of the published data 
on the subject, which is undoubtedly not consistent enough to state whether the 
use of the hypothermic machine perfusion is evidence-based indicated.  
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